Moderna MRNA 深 滬
等待開盤 12-17 09:30:00 美东时间
29.89
-0.030
-0.10%
華盛通- 最 高29.995
- 今 開29.91
- 成交量 721.35万股
- 最 低 29.04
- 昨 收 29.92
- 總市值 116.87亿
- 52周最高 48.92
- 市盈率 靜 --
- 換手率 1.84%
- 52周最低 22.28
- 委 比 59.78%
- 總股本 3.91亿
- 歷史最高 497.49
- 量 比 0.73
- 振 幅 3.19%
- 歷史最低 11.54
- 每 手 1
- 風險率 5.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pfizer leads COVID-19 vaccine peers lower after revamped guidance
A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and Novavax (NVAX) to trade lower on Tuesday, just as a major safety scare related ...
今天 02:37
XOMA Royalty to acquire Generation Bio
XOMA Royalty (XOMA) has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share. Generation Bio stockholders also will receive one non-transferable contingent ...
12-16 06:28
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
12-15 15:30
PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($PYPL) ), ( ($SOUN) ), ( ($MRNA) )...
12-13 17:02
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
FDA officials are weighing a black box warning for Covid vaccines, a proposal that has drawn strong criticism from outside experts citing lack of evidence.
12-13 02:51
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immu...
12-12 23:47
Jefferies Initiates Coverage On Moderna with Hold Rating, Announces Price Target of $30
Jefferies analyst Andrew Tsai initiates coverage on Moderna (NASDAQ:MRNA) with a Hold rating and announces Price Target of $30.
12-12 21:26
电话会总结 ｜ Moderna(MRNA)2024财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Moderna业绩会实录，以下是2024年财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2024年全年总收入32亿美元，同比下降53% - 净产品销售31亿美元，处于修订指引的低端 - 美国市场贡献17亿美元，海外市场贡献14亿美元（其中4亿美元来自不会在2025年重复的预付购买协议） - Q4季度收入9.66亿美元，同比下降66% **盈利能力：** - 2024年全年净亏损36亿美元，每股亏损9.28美元 - Q4净亏损11亿美元，每股亏损2.91美元 - 2024年销售成本15亿美元，占净产品销售的47%（剔除2亿美元非
12-12 12:31
CDC study finds COVID shot significantly reduced ER visits for children
A fresh study authored by CDC scientists is throwing water on the argument that children do not need the COVID-19 vaccine. Investigators examined electronic health records in nine states of emergency ...
12-12 06:37
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.
12-12 02:39
